Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Chemotherapy. Institut Gustave Roussy, University of Paris Sud, Villejuif, France

Survival: 20.0 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: France
City/State/Province: Villejuif
Hospital: Institut Gustave Roussy, University of Paris Sud
Journal: Link
Date: 4/2013

This phase 3 study involved metastatic castration-resistant prostate cancer patients who were divided into two separate treatment groups. Group A consisted of 524 male patients with a median age of 68 years. Group B had 528 male patients with a median age of 68 years.

Patients in group A were treated with the chemotherapy agent docetaxel and the biologic therapy agent zibotentan, which is an inhibitor of the endothelin A receptor and interferes with cancer progression.

Patients in group B were treated with docetaxel and a placebo.

There were two treatment-related deaths due to heart failure in group A. Grade 1-2 alopecia and grade 3-4 peripheral swelling was also reported.

There was one treatment-related death in group B that was due to heart failure. Grade 3-4 neutropenia and leukopenia were also reported.

The median overall survival for groups A and B was 20.0 and 19.2 months, respectively.

This study was supported by AstraZeneca.

Correspondence: Dr. Karim Fizazi; email:

E-mail to a Friend Email Physician More Information